logo-loader
viewXPhyto Therapeutics Corp.

Full interview: Xphyto takes next step to development for rapid test of infectious disease

Xphyto Therapeutics (CSE: XPHY-OTCPINK: XPHYF) CEO Hugh Rogers and Prof. Dr Thomas Beckert, Managing Director of Vektor joined Steve Darling to discuss a definitive development, technology purchase and licence agreement with 3a-Diagnostics GmbH.

Dr Beckert told Proactive how this will work with their thin-film technology and Rogers discuss the next steps of development for the company.

Quick facts: XPhyto Therapeutics Corp.

Price: 2.97 CAD

CSE:XPHY
Market: CSE
Market Cap: $161.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tabula launches new ETF focussing on North American High Yield Credit Market

Tabula Investment Management Limited (LSE: TABS) CEO MJ Lytle joined Steve Darling from Proactive with news the company has started a new ETF that will be exclusively located on the London Stock Exchange under the ticker “TABS”  Lytle telling Proactive that ETF will focus on short exposure...

7 hours, 21 minutes ago

2 min read